Expert perspectives on historical and novel treatment strategies for patients diagnosed with chronic graft-versus-host disease.
April 29th 2022
Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.
Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.
May 6th 2022
Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.
Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.
May 13th 2022
Closing out their discussion on graft-versus-host disease, experts Yi-Bin Chen, MD, and Corey Cutler, MD, MPH, FRCPC, share excitement for future treatment strategies.